Evidence map›Paper›PMID 34788622›Full record

ArticleCell reports2021

Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy.

Yiqun Zhang, Fengju Chen, Erin Pleasance, Laura Williamson, Cameron J Grisdale, Emma Titmuss, Janessa Laskin, Steven J M Jones, Isidro Cortes-Ciriano, Marco A Marra and 1 more

Abstract read
In one paragraph

Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Adaptive DNA amplification of synthetic gene circuit opens a way to overcome cancer chemoresistance.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yiqun ZhangDivision of Biostatistics, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Fengju ChenDivision of Biostatistics, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Erin PleasanceCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, British Columbia, Canada.
Laura WilliamsonCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, British Columbia, Canada.
Cameron J GrisdaleCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, British Columbia, Canada.
Emma TitmussCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, British Columbia, Canada.
Janessa LaskinDepartment of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Steven J M JonesCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, British Columbia, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada; Department of Molecular Biology and Biochemistry, Simon Fraser University, Vancouver, British Columbia, Canada.
Isidro Cortes-CirianoEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge, CB10 1SD, UK.
Marco A MarraCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, British Columbia, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
Chad J CreightonDivision of Biostatistics, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address: creighto@bcm.edu.

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9M
NCI NIH HHS P30 CA125123
6 · The paper itself

Abstract

The global impact of somatic structural variants (SVs) on gene regulation in advanced tumors with complex treatment histories has been mostly uncharacterized. Here, using whole-genome and RNA sequencing from 570 recurrent or metastatic tumors, we report the altered expression of hundreds of genes in association with nearby SV breakpoints, including oncogenes and G-protein-coupled receptor-related genes such as PLEKHG2. A significant fraction of genes with SV-expression associations correlate with worse patient survival in primary and advanced cancers, including SRD5A1. In many instances, SV-expression associations involve retrotransposons being translocated near genes. High overall SV burden is associated with treatment with DNA alkylating agents or taxanes and altered expression of metabolism-associated genes. SV-expression associations within tumors from topoisomerase I inhibitor-treated patients include chromatin-related genes. Within anthracycline-treated tumors, SV breakpoints near chromosome 1p genes include PDE4B. Patient treatment and history can help understand the widespread SV-mediated cis-regulatory alterations found in cancer.

Indexed as

Chromosome AberrationsDatabases, GeneticDNA Copy Number VariationsExome SequencingGene Expression Regulation, NeoplasticGene RearrangementGenome, HumanGenomicsGenomic Structural VariationHumansNeoplasm Recurrence, LocalOncogenesSequence Analysis, RNATranslocation, GeneticWhole Genome Sequencingcancergenomic rearrangementmetastasispan-cancerPOG570recurrencestructural variantsstructural variationtherapywhole genome sequencing

Identifiers

PMID34788622
PMCPMC8630779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.